The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biomarker technologies market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 13% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Biomarker technologies are reliable and cost-effective detection tools that rely on genetic biomarkers, such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), for detecting pathogens. These technologies find extensive application in the early diagnosis of different diseases and disorders. They are also utilized in the drug discovery and development processes and the management of nervous system disorders, cardiovascular diseases, infections, immunological and genetic disorders, and cancer. Some of the commonly used biomarker technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS) and immunoassay.
There is currently a considerable rise in the number of individuals who are suffering from cancer and cardiovascular, neurological, and autoimmune diseases across the globe. This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market. Apart from this, the rising geriatric population is also contributing to the growth of the market. Moreover, there is an increase in research and development (R&D) funding for drug discovery by governing agencies of numerous countries. This, along with the considerably expanding healthcare infrastructure, especially in developing countries, is propelling the market growth. Furthermore, leading market players are introducing numerous advancements in biomarker technologies that provide accurate patient stratification. They are also developing digital biomarkers that aid in collecting objective, quantifiable, physiological, and behavioral data by using digital devices. These digital biomarkers are also incorporated with artificial intelligence (AI), machine learning (ML) solutions for big data analysis, and integrated decision making. Other major factors, including rising awareness about the early detection of cancer for better treatment, and surging income levels of individuals, are projected to impel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarker technologies market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on test type, indication, product, technology and application.
Breakup by Test Type:
Breakup by Indication:
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., LI-COR Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N.V., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Test Type, Indication, Product, Technology, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., LI-COR Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N.V., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at